HR Execs on the Move

Helius Medical

www.heliusmedical.com

 
At Helius Medical Technologies, we`re using the power of our collective curiosity, talent, and experience to change the lives of those affected by neurologic diseases such as traumatic brain injury, multiple sclerosis, stroke, and cerebral palsy. We know how symptoms of these brain disorders can marginalize those affected and we`re committed to changing that dynamic through the development of new neurotech treatments that will reset both the standards and expectations of care. Our first innovation is the Portable Neuromodulation Stimulator, or PoNS®, an investigational, non-invasive therapy that combines stimulation of the trigeminal nerve through the tongue with focused rehabilitation to ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Jeff Mathiesen
Chief Financial Officer Profile
Jeffrey Mathiesen
Chief Financial Officer Profile
Frederick Fantazzia
Vice President of Sales and Marketing, North America Profile

Similar Companies

NYU Columbus Medical Institute of New York

NYU Columbus Medical Institute of New York is a Rego Park, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Riverside County Regional Medical Center

Riverside County Regional Medical Center is a Moreno Valley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Community Hospital of the Monterey Peninsula

Community Hospital of the Monterey Peninsula is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

District One Hospital

District One Hospital provides clinical training for a variety of educational programs. These include Community Health, Emergency Medical Technicians, Medical Technology, Practical Nursing, Social Work and various nursing programs.

Signal Genetics

Signal Genetics is a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. The company was founded in April 2010 after becoming the exclusive licensee to the world-renowned research on multiple myeloma (MM) performed at the University of Arkansas for Medical Sciences (UAMS). Signal Genetics’ flagship product - MyPRS (Myeloma Prognostic Risk Signature) is based upon more than two decades of clinical research on nearly 10,000 MM patients who received their care at UAMS. Signal Genetics offer the MyPRS test out of its state-of-the-art, CLIA certified reference laboratory located in Little Rock, AR. The company is dedicated to making its extensively validated diagnostic services available to all patients who need them. The mission of Signal Genetics is to develop, validate and deliver innovative diagnostic services that enable better patient-care decisions.